MOLECULAR DOCKING–BASED ANALYSIS AND ANTIBACTERIAL ACTIVITY EVALUATION OF RIFAXIMIN

Ashraf, A., Choudhary, A., Khan, M. A., & others. (2024). Repurposing rifaximin against

Klebsiella pneumoniae via targeting of transcription anti-termination protein RfaH for novel antimicrobial development [Preprint]. Research Square. https://doi.org/10.21203/rs.3.rs-4724428/v1

Belogurov, G. A., Vassylyeva, M. N., Svetlov, V., Klyuyev, S., Grishin, N. V., Vassylyev, D. G.,

& Artsimovitch, I. (2007). Structural basis for converting a general transcription factor into an operon-specific virulence regulator. Molecular cell, 26(1), 117-129.

Brown ED, Wright GD (2016). Antibacterial drug discovery in the resistance era. Nature.

;529(7586):336-343.

Calanni, F., Renzulli, C., Barbanti, M., & Viscomi, G. C. (2014). Rifaximin: Beyond the

traditional antibiotic activity. The Journal of Antibiotics, 67(9), 667–670. https://doi.org/10.1038/ja.2014.106

Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., & Darst, S.

A. (2001). Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell, 104(6), 901–912. https://doi.org/10.1016/s0092-8674(01)00286-0

Filimonov DA, Lagunin AA, Gloriozova TA, et al. (2014). Prediction of the biological activity

spectra of organic compounds using the PASS online web resource. Chem Heterocycl Compd. (2014);50(3):444-457.

Fourches D, Muratov E, Tropsha A (2015). Curation of chemogenomics data. Nat. Chem. Biol.

(2015);11(8):535-535.

Gaulton A, Hersey A, Nowotka M, et al. (2017). The ChEMBL database in 2017. Nucleic Acids

Res. (2017);45(D1):D945-D954.

GC, J. B., Bhandari, Y. R., Gerstman, B. S., & Chapagain, P. P. (2014). Molecular dynamics

investigations of the α-helix to β-barrel conformational transformation in the RfaH transcription factor. The Journal of Physical Chemistry B, 118(19), 5101–5108. https://doi.org/10.1021/jp502193v

Gillis, J. C., & Brogden, R. N. (1995). Rifaximin. A review of its antibacterial activity,

pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs, 49(3), 467–484. https://doi.org/10.2165/00003495-199549030-00009

Hirota, S. A. (2016). Understanding the molecular mechanisms of rifaximin in the treatment of

gastrointestinal disorders – A focus on the modulation of host tissue function. Mini-Reviews in Medicinal Chemistry, 16(3), 206–217. https://doi.org/10.2174/1389557515666150722105705

Hoover, W. W., Gerlach, E. H., Hoban, D. J., Eliopoulos, G. M., Pfaller, M. A., & Jones, R. N.

(1993). Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagnostic microbiology and infectious disease, 16(2), 111–118. https://doi.org/10.1016/0732-8893(93)90004-q

Hustmyer, C. M., Wolfe, M. B., Welch, R. A., & Landick, R. (2022). RfaH Counter-Silences

Inhibition of Transcript Elongation by H-NS-StpA Nucleoprotein Filaments in Pathogenic Escherichia coli. mBio, 13(6), e0266222. https://doi.org/10.1128/mbio.02662-22

Jiang, Z. D., & DuPont, H. L. (2005). Rifaximin: in vitro and in vivo antibacterial activity--a

review. Chemotherapy, 51 Suppl 1, 67–72. https://doi.org/10.1159/000081991

Krieger, E., Koraimann, G., & Vriend, G. (2002). Increasing the precision of comparative

models with YASARA NOVA—a self‐parameterizing force field. Proteins: Structure, Function, and Bioinformatics, 47(3), 393-402.

Krieger, E., & Vriend, G. (2014). YASARA View—molecular graphics for all devices—from

smartphones to workstations. Bioinformatics, 30(20), 2981-2982.

Lengauer, T., & Rarey, M. (1996). Computational methods for biomolecular docking. Current

opinion in structural biology, 6(3), 402–406. https://doi.org/10.1016/s0959-440x(96)80061-3

McClure, W. R., & Cech, C. L. (1978). On the mechanism of rifampicin inhibition of RNA

synthesis. The Journal of biological chemistry, 253(24), 8949–8956.

Naqvi, A. A. T., Mohammad, T., Hasan, G. M., & Hassan, M. I. (2018). Advancements in

docking and molecular dynamics simulations towards ligand-receptor interactions and structure-function relationships. Current Topics in Medicinal Chemistry, 18(20), 1755–1768. https://doi.org/10.2174/1568026618666181025114157

Ojetti, V., Lauritano, E. C., Barbaro, F., Migneco, A., Ainora, M. E., Fontana, L., … Gasbarrini,

A. (2009). Rifaximin pharmacology and clinical implications. Expert Opinion on Drug Metabolism & Toxicology, 5(6), 675–682. https://doi.org/10.1517/17425250902973695

Pimentel, M. (2009). Review of rifaximin as treatment for SIBO and IBS. Expert Opinion on

Investigational Drugs, 18(3), 349–358. https://doi.org/10.1517/13543780902780175

Pogodin PV, Lagunin AA, Filimonov DA, Poroikov VV (2015). PASS Targets: Ligand-based

multi-target computational system based on a public data and naïve Bayes approach. SAR QSAR Environ. Res. (2015);26(10):783-793.

Pogodin PV, Lagunin AA, Rudik AV, et al. (2018). How to Achieve Better Results Using PASS-

Based Virtual Screening: Case Study for Kinase Inhibitors. Front. Chem. (2018);6(133):1-14.

Pogodin PV, Lagunin AA, Rudik AV, et al. (2019). AntiBac-Pred: A web application for

predicting antibacterial activity of chemical compounds. J. Chem. Inf. Model. (2019);59(11):4513-4518.

Scarpignato, C., & Pelosini, I. (2005). Rifaximin, a poorly absorbed antibiotic: pharmacology

and clinical potential. Chemotherapy, 51 Suppl 1, 36–66. https://doi.org/10.1159/000081990

Seifi, B., Aina, A., & Wallin, S. (2021). Structural fluctuations and mechanical stabilities of the

metamorphic protein RfaH. Proteins, 89(3), 289–300. https://doi.org/10.1002/prot.26014)

Surette, M. D., Spanogiannopoulos, P., & Wright, G. D. (2021). The enzymes of the rifamycin

antibiotic resistome. Accounts of Chemical Research, 54(9), 2065–2075. https://doi.org/10.1021/acs.accounts.1c00048

Svetlov, D., Shi, D., Twentyman, J., Nedialkov, Y., Rosen, D. A., Abagyan, R., & Artsimovitch,

I. (2018). In silico discovery of small molecules that inhibit RfaH recruitment to RNA polymerase. Molecular microbiology, 110(1), 128–142. https://doi.org/10.1111/mmi.14093

Trott, O., & Olson, A. J. (2010). AutoDock Vina: improving the speed and accuracy of docking

with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry, 31(2), 455-461.

Van Vlem, B., Vanholder, R., De Paepe, P., Vogelaers, D., & Ringoir, S. (1996).

Immunomodulating effects of antibiotics: literature review. Infection, 24(4), 275–291. https://doi.org/10.1007/BF01743360